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Protoporphyria is a genetic disorder in which a deficiency of
mitochondrial ferrochelatase activity causes accumulation
of protoporphyrin that produces severe liver damage in
some patients. In this study, mutations of the ferrochelatase
gene were examined in eight unrelated patients who had
liver transplantation. RNA was prepared from liver and/
or lymphoblasts, and specific reverse transcriptase–nested
polymerase chain reactions amplified and sequenced ferro-
chelatase cDNAs. Products shorter than normal resulted
from an exon 3 deletion in three patients, exon 10 deletion
in two, exon 2 deletion in one, and deletion of five nucle-
otides in exon 5 in one. Sequence of normal-size products re-
vealed no other mutations. Western blot showed a reduced
quantity of normal-size ferrochelatase protein in protopor-
phyria liver compared with normal liver (19–51%, mean










-subunit were not decreased to a similar degree.
Liver ferrochelatase activity was reduced more than could
be explained by the decrease in ferrochelatase protein (4–20%,
mean 9% of normal). These results establish genetic hetero-
geneity in the most severe phenotype of protoporphyria.
However, the gene mutations found share the property of






























Protoporphyria is a genetic disorder that is characterized bio-
chemically by the excessive accumulation and excretion of pro-
toporphyrin, which is the immediate precursor of heme (1).
The bone marrow is the predominant source of the excess pro-
toporphyrin, with a variable contribution coming from the
liver and other heme-forming tissues (2–4). The principle clini-
cal manifestation is photosensitivity, which is caused by the
photoreactive properties of protoporphyrin circulating in der-
mal blood vessels and/or deposited in skin (5, 6). Hepatobiliary
disease may also occur (7, 8), and some patients develop pro-
gressive liver failure that necessitates liver transplantation
(9–11). The liver damage is caused by the toxic effect of proto-
porphyrin on liver structure and function (12, 13).
The enzyme abnormality that underlies protoporphyrin ac-
cumulation in protoporphyria is a deficiency of ferrochelatase





 the last enzyme of the heme biosynthesis path-
way, is located on the matrix side of the inner mitochondrial
membrane and catalyzes the insertion of ferrous iron into pro-
toporphyrin to form heme (16). FC protein has been purified
from several mammalian species, and in all has a molecular
size of 40–42 kD (17). However, radiation inactivation has





 80 kD (18), suggesting that the enzyme exists
as a homodimer in the mitochondrial membrane.
Human FC cDNA has been cloned and sequenced (19). It
has an open reading frame of 1,269 base pairs, which encodes a
protein of 423 amino acid residues, 54 of which are the puta-
tive mitochondrial leader sequence (Fig. 1). The FC gene con-
tains 11 exons, has a minimum size of 45 kb, and maps to chro-
mosome 18 at region q21.3 (20, 21). There is a single gene with
two polyadenylation sites that produce two mRNAs in both
erythroid and nonerythroid cells (20). The deduced amino acid
sequence for human FC has significant homology with FC in
other mammalian species, exhibiting 88% identity to the
mouse enzyme (19) and 86% to the bovine enzyme (22), al-
though the position of the initiator methionine codon is altered
in the bovine nucleotide code (22).
Recent studies have begun to define the molecular causes
of deficient FC activity in patients with protoporphyria (21,
23–32), and genetic heterogeneity has been found. The study
reported here focused on identifying the FC gene defects in
patients with protoporphyric liver disease who required liver
transplantation, in order to determine if specific mutations
were associated with this severe phenotype. The study was ap-
proved by the Institutional Review Boards at The University
of Alabama at Birmingham, the University of Minnesota, and




Patient population and materials.
 
The patient population consisted of
8 individuals, age range 13 years to 51 years, who came to liver trans-
plantation because of advanced protoporphyric liver disease (Table
I). Erythrocyte and serum protoporphyrin levels were measured fluo-
rometrically after solvent partitioning, and liver porphyrin concentra-
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tions were determined fluorometrically after extracting a portion of
tissue with 0.6 N perchloric acid/methanol (1:1, vol/vol) (13). The
erythrocyte, serum, and liver protoporphyrin concentrations in the
patients were markedly increased, and the resected liver specimens
showed features typical of advanced protoporphyric liver disease (7).
The livers were firm in consistency and black in color. Histological
examination revealed finely nodular cirrhosis, cholestasis, and the
presence of birefringent protoporphyrin pigment deposits in hepato-
cytes, Kupffer cells, and biliary structures.
Liver tissue was obtained from each patient, except patient 8, at
the time of liver transplantation. Normal human liver was obtained
from three adult organ donors whose livers were reduced in size for
transplantation into children; cirrhotic liver was obtained from indi-
viduals who underwent liver transplantation because of primary bil-
iary cirrhosis (three cases) and cryptogenic cirrhosis (one case).
These specimens were obtained through the Liver Tissue Procure-
ment and Distribution System at the University of Minnesota, di-
rected by Dr. Harvey Sharp.
Portions of whole liver tissue were rinsed free of blood with nor-








C until studies were carried out. A
portion of whole liver was also processed by differential centrifuga-
tion to obtain a mitochondrial-enriched fraction (33). The mitochon-
drial pellet was suspended in 0.25 M sucrose, 20 mM Tris-Cl (pH 7.5),








C. FC appears to be stable indefi-
nitely in tissue that is kept at this temperature (18).
PMN and mononuclear cells were isolated from heparinized
blood samples by one-step centrifugation for 30 min with Polymorph-
prep (Sigma Chemical Co., St. Louis, MO) (34). Total RNA was ex-
tracted from mononuclear cells and whole liver tissue (35), and ge-
nomic DNA was extracted from PMN and whole liver tissue (36).
The peripheral blood sample was also used to establish EBV–trans-
formed lymphoblasts (EBVTL) from five patients (37), which were
used as an additional source of RNA and genomic DNA. A mononu-
clear cell preparation was prepared from heparinized blood samples
from five healthy individuals, and EBVTL from 5 individuals with
nonporphyric disorders (colon cancer, Wilms’s tumor, lysencephalop-
athy, albinism, and asthma).
 
Measurement of FC activity.
 
FC activity was measured in mito-
chondrial fractions prepared from the seven protoporphyric livers,
three normal livers, and four cirrhotic livers based on a modification
of the pyridine hemochromogen method of Porra and Jones (38). The
assay mixture contained 50 mM Tris-Cl (pH 8.1), 1% sodium cholate,









rin, and 1.0–2.0 mg of liver mitochondrial protein in a final volume of





C and was terminated by the addition of 33 mM iodoaceta-
mide in 33 mM EDTA (final concentration). The difference spectrum
between the reduced and oxidized pyridine hemochromogen was re-
corded using a spectrophotometer (Beckman Instruments, Fullerton,
CA). The protein concentration of each mitochondrial sample was
quantitated by the bicinchoninic acid method (39).
FC activity in EBVTL was measured by the formation of zinc
deuteroporphyrin. EBVTL were cultured to a quantity of approxi-
mately 30 million cells, centrifuged, resuspended in 0.5 ml of solution
Figure 1. Structure of human FC cDNA, 
showing the exon sequences and bound-
aries, the end of the putative mitochondrial 
leader sequence (*), and positions of the 
primers used in the RT-PCR to synthesize 
and amplify overlapping FC cDNA se-
quences. (a) Primer location for RT of FC 
mRNA; (b) primer locations to synthesize 
and amplify the full-length coding se-
quence of FC cDNA; (c1, c2) primer loca-
tions used in the nested PCR to synthesize 
and amplify the 59 and 39 portions of FC 
cDNA, respectively.
 




















1 51 M 5276 160 3957
2 38 F 5131 144 5894
3 15 M 6470 236 4599
4 18 F 6488 836 2606
5 13 M 7679 448 5226
6 14 F 2450 95 4402
7 36 F 8240 362 1708
8 27 M 6094 226 —
Normal/control 20–65 0 0.2–1.0
 




containing 150 mM NaCl, 40 mM Tris-Cl (pH 7.5), and sonicated on
ice. Sodium cholate was added to a concentration of 1%, and the
sample was vortexed to solubilize ferrochelatase. The sonicate from
six million cells was used in each assay mixture. The same amount of
boiled sonicate was used to measure nonenzymatic formation of zinc
deuteroporphyrin. The sonicated mixture was added to stoppered





of 5 mM deuteroporphyrin was added. The tubes were flushed with




l of 5 mM
zinc sulfate dissolved in 5% ascorbic acid to achieve a reaction vol-
ume of 2 ml (final concentrations of deuteroporphyrin and zinc were








C for 1 h, the re-
action was stopped by adding EDTA to the reaction flask in a con-




M, followed by 2 ml of absolute ethanol. The solu-




 for 10 min, and the supernatant was
examined by fluorescence spectroscopy using a spectrofluorometer
(4818 photomultiplier tube, Farrand; RCA Distributor and Special
Products Division, Camden, NY), with excitation at 405 nM and
emission scanned from 550 to 700 nM. The amount of zinc deu-
teroporphyrin formed enzymatically was determined by comparing
the fluorescence units to a zinc deuteroporphyrin standard and sub-





Anti-FC antibody was made against purified bo-
vine FC as previously described (18, 33, 40). Liver tissue and refer-
ence proteins were subjected to PAGE according to the method of
Laemmli (18, 33, 41). 0.1-g portions of whole liver were sonicated in





tal protein were combined with an equal volume of solution that con-
tained 125 mM Tris-Cl (pH 6.8), 20% glycerol, 4.6% SDS, and 6.0%
2-mercaptoethanol and boiled for 3 min. After 10% SDS-PAGE, the
gel was electrophoretically transferred to nitrocellulose or polyvinyl-
lidene difluoride (PVDF) membranes (Millipore Company, Bed-
ford, MA). After blocking the membrane with 5% nonfat dry milk
in 10 mM PBS (pH 7.4), the membrane was incubated for 3 h with
anti–FC antiserum diluted 1:500 in 5% nonfat dry milk. The mem-
brane was then washed and incubated for 1 h with goat anti–rabbit
IgG conjugated with HRP and developed using peroxidase substrate
(100 mM Tris-Cl [pH 7.4], 0.8 mg/ml 3,3-diaminobenzidine, 0.2 mg/ml
nickel chloride, 0.01% hydrogen peroxide). The density of the stain-
ing was determined by video densitometry (Model GS-670; Bio-Rad
Laboratories, Hercules, CA).









-subunit. This was supplied by Dr. Douglas Cyr
of the University of Alabama at Birmingham (42). This peptide, like






nested PCR (RT-PCR) provided template for direct sequencing of
FC cDNA (Fig. 1). This PCR method was developed to optimize the
size of DNA used in amplification and sequencing. It also allowed
amplification of FC mRNA in EBVTL, where FC is a rare mRNA as
shown by Northern blot. Total RNA was isolated from whole liver





g of the RNA. The reactions were carried out in a thermal cycler
(Perkin-Elmer Corp.; Norwalk, CT) under sterile mineral oil overlay,
using the Gene Amp RNA PCR Kit and RNA PCR Core Kit (Per-
kin-Elmer Corp., Branchbury, NJ). All reactions had a negative con-
trol (no template added) run at the same time. The RT reaction was




l and contained 25 pmol of a specific




 to the coding region (Fig. 1). It was









5 min to destroy the enzymes and RNA. The full-length first-cycle
PCR reaction was then done using the entire product from the RT re-




l and contained 50




 primer and an additional 50 pmol of the RT














C for 1 min, 15 s. Nested PCR were then carried out using 5–10%
of the first cycle PCR product as template. The primer pairs were








 portion of FC
cDNA respectively (Fig. 1). The reactions were carried out in a vol-




l containing 75 pmol of each primer. They consisted of




C for 10 s, an-








C for 50 s.
The PCR products were subjected to electrophoresis on 0.8%
agarose gel and stained with ethidium bromide. The products of the
expected 1-kb size, as well as products of smaller size were excised
from the gel and purified using the Geneclean procedure (Bio 101
Inc.; La Jolla, CA). Direct sequencing was performed using an ABI





g of the PCR product and 3.2 pmol of primer. Base assign-
ment was done by ABI computer software, visually inspected, and




Genomic DNA was prepared from
liver, polymorphonuclear leukocytes, and EBVTL. Oligonucleotides









were synthesized (Table II). PCR was carried out using GeneAmp
PCR Core Reagents (Perkin-Elmer Corp.) and a GeneAmp PCR
System 9600 (Perkin-Elmer Corp.). Some reactions were amplified
with TaqPlus Long PCR System in low-salt reaction buffer (Strat-
agene Corp., La Jolla, CA). The amplified products were analyzed
for appropriate size on a 1% agarose gel. The PCR product was li-
gated and transformed using a TA Cloning Kit (Invitrogen, Carlsbad,
CA). Colonies containing PCR inserts were grown overnight in LB
medium with carbenicillin and DNA extracted with a Wizard Plus
Minipreps DNA Purification System (Promega Biotec; Madison,
WI). DNA was sequenced with automated sequencing (ABI) and the
 
Table II. Primers Used to Sequence Genomic FC DNA
 
Exon and flanking
intron sequences Primer type Primer sequence Primer location
 

















119 downstream to exon 2

















95 downstream to exon 3

















34 downstream to exon 5

















87 downstream to exon 7 (ref. 27)



















exon and flanking introns were evaluated for mutations. Three to
eight genomic DNA clones were sequenced to evaluate each abnor-




Porphyrins and porphyrin standards were obtained
from Porphyrin Products, Inc. (Logan, UT). RPMI 1640, penicillin,
and streptomycin used in lymphoblast culture were obtained from
Gibco Life Technologies-BRL (Gaithersburg, MD). Fetal bovine
serum came from Hyclone Laboratories, Inc. (Logan, UT). Goat
anti–rabbit IGG conjugated with HRP was obtained from Bio-Rad
Laboratories. Perchloric acid and methanol were obtained from Fisher
Scientific (Pittsburgh, PA). All other reagents were from Sigma









SEM. Statistical comparisons between groups were done










FC cDNA amplified by RT-PCR from
mononuclear cells of five healthy individuals and EBVTL of
five control individuals had the same sequence as originally re-
ported (19), with the exception that guanine replaced adenine
at cDNA position 287 in all of the samples. This codes for argi-
nine at amino acid 96 instead of glutamine, in agreement with
2 other reports (23, 31). It is probably the more common se-
quence for FC cDNA, at least in Western patients. Thus EBV
transformation of lymphocytes did not cause mutations in the
FC gene, which would confound the identification of genetic
defects.
RT-PCR demonstrated products shorter than the expected
1,000 bases in FC cDNA prepared from liver tissue of six pa-
tients with protoporphyria (patients 1–4, 6, 7 in Table I). This
was also found in FC cDNA prepared from EBVTL of three
patients (patients 2–4) and from EBVTL of the patient in
whom liver tissue was not obtained at the time of transplanta-
tion (patient 8). The short products were visible on ethidium
bromide staining of the agarose gel and could be separated
from the products of normal length (Fig. 2), with the exception
of patient 7.
Sequencing showed that the short products were caused by
 
an exon 3 deletion in patients 1, 2, and 6 (Fig. 3 and Table III).
The sequence of the normal-size products generated by RT-
PCR in each of the patients revealed no other mutations in FC
cDNA. Thus, they appear to be heterozygous for a mutation
causing an exon 3 deletion. To investigate the cause of the
variant FC cDNA, exon 3 and its flanking intron regions were
amplified from genomic DNA templates and ligated into a
plasmid. Clones that contained the amplified products were
isolated and sequenced. In patients 1 and 2, half of the clones
had the normal sequence, whereas the rest had a mutation in
the consensus sequence of the highly conserved splice site (Ta-
ble III), as was previously reported in a patient who was het-
erozygous for an exon 3 deletion (31). In patient 6 the only ab-
normality found was a transversion of A to C at position 6 in
intron 3. Although this may be just a polymorphism and not a
mutation that causes a splicing defect, the same transversion
was not found in the remaining patients or in the healthy/con-
trol individuals. Nevertheless, confirmation that this is the
splicing defect will require in vitro splicing experiments.
Sequencing of the short products generated by RT-PCR
demonstrated an exon 10 deletion in patients 4 and 8, and an
exon 2 deletion in patient 3 (Table III). The sequence of the
normal-size products in these patients revealed no other muta-
tions in FC cDNA, and thus they also appear to be heterozy-
gous for FC gene mutations. The mutation found in patient 4










was previously reported in a patient heterozygous for this mu-
tation (26). Patient 8 had a deletion of this nucleotide or the
next nucleotide, indicating that this part of exon 10 is critical to
normal splicing.
In patient 7, the first attempt at amplification of FC cDNA
by RT-PCR also demonstrated a product shorter than the ex-
pected 1,000 bases, and sequence of the short product demon-
strated a deletion of exon 7. However, on the subsequent five
occasions in which RT-PCR was used to amplify FC cDNA,
only a product that appeared to be normal in length was found.
To clarify this, the RT-PCR products were ligated with vector
PCR 2.1, (Invitrogen) and plasmid inserts containing cDNAs
Figure 2. Ethidium bromide stain
of the 59 products generated from 
RT-PCR reactions used to amplify 
FC cDNA in a patient with exon 3 
deletion (patient 2). (Lanes 1 and 2) 
Normal FC cDNA species showing 
the expected 1,000-base product; 
(lanes 3 and 4) FC cDNA species 
from patient who is heterozygous 
for exon 3 deletion, showing a short 
product in addition to the normal-
length product; (Lane 5) DNA stan-
dards. Both the normal and short 
products hybridized with radiola-
beled FC cDNA.
 




were sequenced. Half had the normal sequence for FC cDNA,
whereas the rest had a deletion of nucleotides 580–584 in exon
5. This deletion produces a frame shift in FC mRNA, which is
predicted to cause the formation of a truncated protein that is
208 amino acids long (Table III). None of the FC cDNA in-
serts had an exon 7 deficiency, but all contained a silent trans-




C). Sequencing of four
clones of exon 5 and the flanking intron regions confirmed that
the patient was heterozygous for a deletion of nucleotides 580–
584. Sequencing of eight clones of exon 7 and the flanking in-
tron regions also confirmed the presence of the silent transver-
sion at position 798, but no mutation was found either in the
donor splice site of intron 7 or the acceptor splice site of intron
6. The reason for the deletion of exon 7 found on one occasion
by RT-PCR analysis is thus uncertain, but may reflect a low-
level expression of abnormal mRNA, which occurred because
of a spontaneous splicing abnormality rather than a true gene
mutation.
In patient 5 no abnormality was found by RT-PCR in FC
cDNA prepared from either liver tissue or EBVTL. Moreover,
no abnormality was found when each of his exons and flanking
intron regions was examined by analysis of genomic DNA, in-
cluding exons 1 and 11.
 
Western blot analysis of hepatic FC.
 
The effect of the mu-
tations on FC gene expression was evaluated by Western blot
of FC protein in liver tissue from seven protoporphyric pa-
tients and three normal livers. None of the patients was found
to have a peptide shorter than the normal 42-kD FC protein
(Fig. 4). This indicated that the mutant proteins (Table III) ei-
ther were rapidly destroyed after translation, or were not reac-
tive with the polyclonal antibody that recognized the normal
protein.
The level of the normal-size 42-kD protein in liver tissue of
each of the patients, including patient 5 in whom no abnormal-
ity in FC cDNA was identified, was significantly reduced com-
pared with that in normal liver tissue (Fig. 5). The range, as de-
Figure 3. Sequence analysis of the short 
FC cDNA product in patient 2 demon-
strated it to have a deletion of 120 bases 
(segment enclosed by arrows correspond-
ing to exon 3). The sequence of the anti-
sense strand is shown.
 
Table III. FC Gene Mutations and Their Effect on FC Protein in Patients with Protoporphyric Liver Disease
 
Patient FC cDNA sequence Genomic FC DNA sequence Effect on FC protein
 










G R65S and deletion of aa* 66–105










G R65S and deletion of aa 66–105










G Truncated protein 29 aa long




 T Deletion of aa 360–379












 C R65S and deletion of aa 66–105
7 580del5 580del5 Truncated protein 208 aa long











termined by four separate determinations in each patient, was









 0.006 compared to normal).








-subunit were not similarly re-
duced, varying from 63 to 100% of normal, with a mean of
78% for the group (Fig. 5). Thus, the decrease in the levels of
normal FC protein in the livers of protoporphyric patients was
due mainly to the FC gene mutations and not to a nonspecific
effect of protoporphyric liver disease on mitochondrial pro-




The levels of FC activity in the mito-
chondrial-enriched fractions of livers of patients with proto-
porphyria were compared with those of three normal livers
and livers of four patients with other causes of cirrhosis who
came to liver transplantation. The levels in the three normal
livers were 14.57, 16.73, and 17.88 nanomoles deuteroheme per
milligram protein per hour as determined by three separate
determinations (mean level for the group, 16.39) (Table IV).









SEM). In contrast, FC activity in the liver of each pa-
tient with protoporphyria was significantly reduced compared
with FC activity in normal livers as determined by three or
more separate measurements, varying from 4 to 20% of nor-
mal (mean 9%, P , 0.0007) (Table IV).
The protoporphyrin content of the mitochondrial fractions
from the patients with protoporphyric liver disease was in-
creased, ranging from 1.1 to 5.0 mg/mg protein (level in normal
mitochondrial fractions was , 0.02 mg/mg protein). However,
this contributed a concentration of only 2.0–9.0 mM in the as-
say for FC activity, significantly less than the concentration of
deuteroporphyrin that was used in the assay (170 mM).
The levels of FC activity in sonicated EBVTL of five pa-
tients with protoporphyria were also significantly decreased
compared with those in three normal lines (P , 0.0005) (Table
IV). EBVTL from the patients grew normally and did not ac-
cumulate protoporphyrin under the standard culture condi-
tions. However, when porphyrin biosynthesis was stimulated
by incubating the EBVTL with 1.0 mM D-aminolevulinic acid
for 24 h in the presence of 50 mM iron, the five protoporphyria
lines accumulated a significantly greater amount of protopor-
phyrin than the three normal lines (1376680 versus 6176163
pmol/mg protein, mean6SEM, P , 0.005).
Discussion
This study examined mutations in the FC gene in eight pa-
tients with protoporphyric liver disease who had liver trans-
plantation. Different mutations were found (Table III), indi-
cating that genetic heterogeneity exists in the most severe
phenotype of protoporphyria. The mutations found share the
property of causing a major structural alteration in the FC pro-
tein.
Exon deletions appear to be common in general in proto-
porphyria (28). However, in 29 patients without apparent liver
disease in whom the FC gene defect was identified (21, 23, 24,
26–29, 31, 32), only one patient demonstrated an exon 3 dele-
tion (P , 0.03 by Fisher’s exact test when compared with the
patients in the present study). That patient was an 11-yr-old fe-
male with severe photosensitivity whose FC activity in periph-
Figure 4. Western blot of normal human liver tissue (lane 1), liver tis-
sue from seven patients (lanes 2–8) and mitochondrial extract from 
bovine liver (lane 9). Homogenized whole liver (400 mg) was loaded 
on each lane. First antibody was prepared against purified bovine 
liver FC in rabbits. A 42-kD FC protein was identified in patients and 
normal human liver. No shorter peptides were demonstrated.
Figure 5. (Top) Quantitation of the amount of FC protein in liver tis-
sue from seven patients and normal human liver tissue was done by 
Western blot. Measurement was done on 50 mg total protein pre-
pared from whole liver homogenate. The density of the staining of 
the FC band was determined using video densitometry. The level of 
FC in liver tissue of each patient (four determinations) was expressed 
as the percent of the mean level in three normal human livers. (Bot-
tom) Quantitation of the amount of ATPase F1-b protein in liver tis-
sue from the patients was also done by Western blot. Measurement 
was done on 50 mg total protein prepared from whole liver homoge-
nate. The level in each patient (two determinations) was expressed as 
the percent of the mean level in three normal human livers.
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eral blood monocytes was only 11.7% of normal (31). Thus it
will be important to follow her for signs of liver disease.
FC gene mutations have previously been identified in a
limited number of patients with protoporphyric liver disease.
The first case, reported by Nakahashi and co-workers (25),
had a mutation at the donor site of intron 9 which resulted in
the deletion of exon 9. Schneider-Yin et al. reported a patient
with a point mutation (175C→T) that caused a stop codon that
produced a truncated protein (43). Sarkany et al. described
two siblings that were compound heterozygotes for an exon 10
deletion and developed liver failure in adolescence (30); and
proposed that recessive inheritance may be an important fac-
tor that predisposes patients with protoporphyria to develop
liver disease. However, the patients reported by Nakahashi et
al. (25) and Schneider-Yin et al. (43) both had autosomal dom-
inant inheritance (44). Moreover, no patient in the present
study had evidence for recessive inheritance. Thus recessive
inheritance may predispose patients with protoporphyria to
develop liver disease but does not appear to be required nor to
account for most of the cases.
Liver tissue was obtained from seven patients at the time of
transplantation, permitting study of the effect of the mutations
on FC gene expression. Proteins of shorter length than normal,
which would be formed as a result of the mutations (Table III),
were not detected using antibody that was made against nor-
mal bovine FC protein (18, 33). The antibody cross-reacts with
the normal human protein because of the significant homology
that exists between bovine and human FC (22). The mutant
proteins may have been rapidly catabolized after translation.
Alternatively, the mutations caused such alterations in the
structure of the proteins that they would not react with the an-
tibody.
Western blot analysis also showed that levels of the normal
FC protein were significantly reduced, as was predicted. Some
patients, in particular patient 4, had levels much lower than the
50% of normal which would be expected from a heterozygote
with one normal allele and one mutant allele. The genetic as-
pects of disease expression in protoporphyria have long been
considered to be complex, and Went and Klasen in 1984 pro-
posed a three-allele system based on a study of 91 families
(45). Gouya et al. subsequently presented evidence for modu-
lation of the phenotype by low expression of the normal FC al-
lele in a family in which the FC gene mutation caused exon 10
skipping (32). This could explain the low level of normal FC
protein in patient 4, who also had exon 10 skipping, as well as
the variability in the remainder of the patients. It is possible
that liver disease also contributed to the variable level of nor-
mal FC protein, since another mitochondrial protein (F1-ATP-
aseb-subunit) was lower than normal in most of the patients.
FC activity in liver tissue was depressed even more than the
level of FC protein. Due to the significant structural alter-
ations, the mutant proteins should not have enzyme activity.
However, the protein expressed by the normal allele would be
expected to function normally unless modified by additional
factors. The finding that EBVTL from the patients had a
marked deficiency of FC activity suggests that other genetic
factors are important. Protoporphyric liver damage may also
be a factor. Previous studies indicated that the decrease in liver
FC activity roughly correlated with the degree of liver damage
in patients with protoporphyria, being most pronounced when
cirrhosis was present (15, 46). Thus acquired factors could fur-
ther inhibit the residual FC activity as the liver disease
progresses. Human FC has an iron sulfur cluster that binds ni-
tric oxide, causing inactivation of the enzyme (47), and genera-
tion of nitric oxide in damaged liver tissue might be one such
factor. Another could be a change in the phospholipid fatty
acyl composition of the mitochondrial membrane (48). Se-
quential measurements of hepatic FC activity have not been
made in patients with progressive liver disease, which would
help to answer this question.
The mutations also affect FC gene expression in bone mar-
row erythroid cells, which are the major source of excess pro-
toporphyrin in most patients with protoporphyria (49). The
abnormality in bone marrow persists after liver transplanta-
tion, and the patients continue to have elevated levels of eryth-
rocyte protoporphyrin (11). Interpreting the cause of proto-
porphyrin accumulation in erythroid cells is complicated,
because induction of FC and the other enzymes of the heme
biosynthesis pathway occurs during erythroid differentiation
(50, 51). The major accumulation of protoporphyrin in the de-
veloping erythrocyte occurs soon after the loss of the nucleus
(52). Thus the degree of protoporphyrin accumulation in
erythroid cells of patients with protoporphyria probably de-
pends both on the effect of the gene mutation and on the pat-
tern of induction of FC relative to the other enzymes in the
heme biosynthesis pathway.
In summary, this study shows that the FC gene mutations
found in patients with protoporphyria who have severe liver
disease produce major structural alterations in FC protein.
This is associated with a significant decrease in the level of the
normal liver FC protein and in liver FC activity. Thus, the liver
probably contributes to the overproduction of protoporphyrin
that results in its own damage, and this may increase as liver
damage progresses.
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ner) from the National Institutes of Health, the Cecil J. Watson Lab-
oratory Endowment Fund, and the Adrian Bennett Memorial Fund.
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